Biogen Inc. Reports Second Quarter 2026 Financial Results

Biogen Inc. announced its financial results for the second quarter ended June 30, 2026. Total revenue reached $2.7 billion, a 3% increase year-over-year, with the Growth Portfolio contributing $1.06 billion, up 24% year-over-year. Key product highlights include SPINRAZA revenue of $402 million (up 2%), LEQEMBI global sales of $184 million (up 15%), SKYCLARYS revenue of $168 million (up 29%), ZURZUVAE revenue of $71 million (up 53%), SYFOVRE revenue of $162 million, and EMPAVELI revenue of $46 million. The company reported GAAP diluted EPS of $0.66 and Non-GAAP diluted EPS of $3.60. Biogen is advancing its late-stage pipeline with five registrational readouts expected in the next four quarters. The Apellis acquisition is progressing, with integration on track and expected to be accretive to Non-GAAP diluted EPS in 2027. Full year 2026 guidance for Non-GAAP diluted EPS has been updated to a range of $12.00 to $13.00.